Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Xencor Inc's Business Segments
Xencor Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 5
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 5 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Royalty97.8%
- License2.2%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 4 | 97.8% |
| License | $ 0 | 2.2% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Xencor Inc
Xencor Inc is a biopharmaceutical company that uses its proprietary XmAb technology platform to develop and commercialize novel antibody therapeutics. The company's mission is to improve patient outcomes and quality of life by developing innovative and differentiated therapeutics.
Xencor's XmAb technology platform is a versatile antibody engineering technology that enhances the efficacy and safety of antibodies. It can be used to improve the half-life of antibodies, increase their potency, and reduce their immunogenicity. The XmAb technology platform has been applied to the development of several antibody candidates in various therapeutic areas including oncology, autoimmune diseases, and allergic diseases.
One of the key strengths of Xencor is its collaboration strategy. The company has partnered with several pharmaceutical and biotechnology companies including Novartis, Alexion Pharmaceuticals, and MorphoSys to develop and commercialize XmAb-based therapeutics. Xencor has also entered into research collaborations with academic institutions and government agencies.
Xencor has a diverse pipeline with several candidates in different stages of clinical development. The company's lead candidate, XmAb5871, is a first-in-class monoclonal antibody that targets the FcγRIIb receptor on B cells. It is being developed for the treatment of autoimmune diseases including systemic lupus erythematosus and IgG4-related disease. XmAb7195 is another candidate being developed in collaboration with Novartis for the treatment of acute myeloid leukemia and other hematologic malignancies.
In addition to its pipeline of candidates, Xencor also has a robust technology portfolio. The company has developed several proprietary technologies including Xtend™ Fc technology, which extends the half-life of antibodies, and bispecific Fc technology that enables the creation of bispecific antibodies with improved therapeutic properties.
Overall, Xencor is a leading biopharmaceutical company with a promising pipeline of candidates and innovative technology platform. The company's collaborations, proprietary technologies, and diverse pipeline positions it to continue to deliver value to patients and shareholders in the years to come.
Xencor's XmAb technology platform is a versatile antibody engineering technology that enhances the efficacy and safety of antibodies. It can be used to improve the half-life of antibodies, increase their potency, and reduce their immunogenicity. The XmAb technology platform has been applied to the development of several antibody candidates in various therapeutic areas including oncology, autoimmune diseases, and allergic diseases.
One of the key strengths of Xencor is its collaboration strategy. The company has partnered with several pharmaceutical and biotechnology companies including Novartis, Alexion Pharmaceuticals, and MorphoSys to develop and commercialize XmAb-based therapeutics. Xencor has also entered into research collaborations with academic institutions and government agencies.
Xencor has a diverse pipeline with several candidates in different stages of clinical development. The company's lead candidate, XmAb5871, is a first-in-class monoclonal antibody that targets the FcγRIIb receptor on B cells. It is being developed for the treatment of autoimmune diseases including systemic lupus erythematosus and IgG4-related disease. XmAb7195 is another candidate being developed in collaboration with Novartis for the treatment of acute myeloid leukemia and other hematologic malignancies.
In addition to its pipeline of candidates, Xencor also has a robust technology portfolio. The company has developed several proprietary technologies including Xtend™ Fc technology, which extends the half-life of antibodies, and bispecific Fc technology that enables the creation of bispecific antibodies with improved therapeutic properties.
Overall, Xencor is a leading biopharmaceutical company with a promising pipeline of candidates and innovative technology platform. The company's collaborations, proprietary technologies, and diverse pipeline positions it to continue to deliver value to patients and shareholders in the years to come.
Xencor Inc. is a biopharmaceutical company that is dedicated to the development of next-generation biologic drugs, specifically targeting various cancer types and autoimmune diseases. The company leverages its proprietary XmAbe technology platform to innovate and enhance the efficacy, safety, and half-life of antibodies and therapeutically relevant proteins. Below is an extensive overview of Xencors business segments, products, and services:
Segments
1. Oncology:
Xencor has a strong focus on immuno-oncology, which aims to harness and augment the bodys immune system to fight cancer. The company is developing a range of antibody-drug conjugates (ADCs) designed to provide targeted treatment for different cancer types. These ADCs link potent cytotoxic agents to antibodies that specifically recognize tumor-associated antigens, thereby enabling a more precise attack on cancer cells. This innovative approach aims to enhance therapeutic effectiveness while reducing the adverse impacts often associated with conventional chemotherapy, including toxicity to healthy tissues.
2. Autoimmune Diseases:
In the realm of autoimmune diseases, Xencor is investigating therapeutic options that modulate the immune response to address disorders characterized by immune system dysregulation. The lead candidate in this segment is XmAbe5871, a monoclonal antibody that selectively targets CD19, a protein prevalent on B-cells. CD19 plays a significant role in the activation and differentiation of B-cells, and its modulation has potential benefits in treating a variety of autoimmune conditions. The focus on this mechanism underscores Xencor’s commitment to developing targeted therapies that can improve patient outcomes in challenging disease areas.
Products
1. XmAbe Technology Platform:
The XmAbe platform is a cutting-edge suite of modifications and engineering techniques that can be applied to therapeutic proteins to optimize their characteristics. This platform enhances several key attributes of biologics:
- Potency: By enhancing binding affinity and functional activity, Xencor improves the overall therapeutic effect of its drug candidates.
- Safety: The technology reduces unwanted immune responses, decreasing the risk of adverse reactions in patients.
- Half-Life: XmAbe technology improves pharmacokinetics, allowing drugs to remain active in the body for extended periods, which can reduce dosing frequency and improve patient compliance.
2. XmAbe Antibody-Drug Conjugates (ADCs):
Xencor’s ADCs represent a strategic blend of targeted therapy and cytotoxic action. Each ADC uses an antibody to selectively deliver a cytotoxic drug to cancer cells, minimizing exposure to normal, healthy cells. This targeted approach can result in superior efficacy and a more favorable safety profile compared to conventional chemotherapy methods.
3. XmAbe Fusion Proteins:
The XmAbe fusion proteins are designed to combine different functional domains within a single therapeutic molecule to tackle complex disease pathways. These molecules are crafted to engage multiple mechanisms of action, thus potentially offering enhanced therapeutic outcomes for patients suffering from cancer and autoimmune diseases.
Services
1. Collaborative Partnerships:
Xencor actively engages in collaborative partnerships with pharmaceutical and biotechnology companies to utilize its technology platform in various drug discovery and development initiatives. Through these collaborations, Xencor provides extensive expertise in areas such as antibody engineering, biomarker analysis, and preclinical development services. This synergistic approach allows partners to leverage Xencors innovative capabilities to advance their own therapeutic goals in numerous therapeutic areas.
2. Contract Manufacturing:
Xencor also offers comprehensive contract manufacturing services for biologic drugs, including monoclonal antibodies, ADCs, and fusion proteins. Their state-of-the-art manufacturing facilities are equipped to handle the production of these biologics at both clinical and commercial scales, ensuring high-quality output that meets regulatory standards. This service aspect of their business is crucial for fulfilling the growing demand for advanced biologic therapeutics in the market.
In summary, Xencor Inc. is positioned at the forefront of biopharmaceutical innovation through its commitment to developing sophisticated, next-generation biologic drugs aimed at treating complex conditions such as cancer and autoimmune diseases. By integrating advanced technologies with collaborative efforts and manufacturing capabilities, Xencor continues to expand its influence in the biotechnology sector.
Segments
1. Oncology:
Xencor has a strong focus on immuno-oncology, which aims to harness and augment the bodys immune system to fight cancer. The company is developing a range of antibody-drug conjugates (ADCs) designed to provide targeted treatment for different cancer types. These ADCs link potent cytotoxic agents to antibodies that specifically recognize tumor-associated antigens, thereby enabling a more precise attack on cancer cells. This innovative approach aims to enhance therapeutic effectiveness while reducing the adverse impacts often associated with conventional chemotherapy, including toxicity to healthy tissues.
2. Autoimmune Diseases:
In the realm of autoimmune diseases, Xencor is investigating therapeutic options that modulate the immune response to address disorders characterized by immune system dysregulation. The lead candidate in this segment is XmAbe5871, a monoclonal antibody that selectively targets CD19, a protein prevalent on B-cells. CD19 plays a significant role in the activation and differentiation of B-cells, and its modulation has potential benefits in treating a variety of autoimmune conditions. The focus on this mechanism underscores Xencor’s commitment to developing targeted therapies that can improve patient outcomes in challenging disease areas.
Products
1. XmAbe Technology Platform:
The XmAbe platform is a cutting-edge suite of modifications and engineering techniques that can be applied to therapeutic proteins to optimize their characteristics. This platform enhances several key attributes of biologics:
- Potency: By enhancing binding affinity and functional activity, Xencor improves the overall therapeutic effect of its drug candidates.
- Safety: The technology reduces unwanted immune responses, decreasing the risk of adverse reactions in patients.
- Half-Life: XmAbe technology improves pharmacokinetics, allowing drugs to remain active in the body for extended periods, which can reduce dosing frequency and improve patient compliance.
2. XmAbe Antibody-Drug Conjugates (ADCs):
Xencor’s ADCs represent a strategic blend of targeted therapy and cytotoxic action. Each ADC uses an antibody to selectively deliver a cytotoxic drug to cancer cells, minimizing exposure to normal, healthy cells. This targeted approach can result in superior efficacy and a more favorable safety profile compared to conventional chemotherapy methods.
3. XmAbe Fusion Proteins:
The XmAbe fusion proteins are designed to combine different functional domains within a single therapeutic molecule to tackle complex disease pathways. These molecules are crafted to engage multiple mechanisms of action, thus potentially offering enhanced therapeutic outcomes for patients suffering from cancer and autoimmune diseases.
Services
1. Collaborative Partnerships:
Xencor actively engages in collaborative partnerships with pharmaceutical and biotechnology companies to utilize its technology platform in various drug discovery and development initiatives. Through these collaborations, Xencor provides extensive expertise in areas such as antibody engineering, biomarker analysis, and preclinical development services. This synergistic approach allows partners to leverage Xencors innovative capabilities to advance their own therapeutic goals in numerous therapeutic areas.
2. Contract Manufacturing:
Xencor also offers comprehensive contract manufacturing services for biologic drugs, including monoclonal antibodies, ADCs, and fusion proteins. Their state-of-the-art manufacturing facilities are equipped to handle the production of these biologics at both clinical and commercial scales, ensuring high-quality output that meets regulatory standards. This service aspect of their business is crucial for fulfilling the growing demand for advanced biologic therapeutics in the market.
In summary, Xencor Inc. is positioned at the forefront of biopharmaceutical innovation through its commitment to developing sophisticated, next-generation biologic drugs aimed at treating complex conditions such as cancer and autoimmune diseases. By integrating advanced technologies with collaborative efforts and manufacturing capabilities, Xencor continues to expand its influence in the biotechnology sector.